- Home
- PALI vs MDXH Comparison
PALI vs MDXH Comparison
Compare PALI & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PALI
- MDXH
- Stock Information
- Founded
- PALI 1996
- MDXH 2003
- Country
- PALI United States
- MDXH Belgium
- Employees
- PALI N/A
- MDXH N/A
- Industry
- PALI Biotechnology: Biological Products (No Diagnostic Substances)
- MDXH
- Sector
- PALI Health Care
- MDXH
- Exchange
- PALI Nasdaq
- MDXH Nasdaq
- Market Cap
- PALI 212.0M
- MDXH 203.4M
- IPO Year
- PALI N/A
- MDXH 2021
- Fundamental
- Price
- PALI $1.96
- MDXH $4.77
- Analyst Decision
- PALI Strong Buy
- MDXH Buy
- Analyst Count
- PALI 2
- MDXH 1
- Target Price
- PALI $12.00
- MDXH $6.00
- AVG Volume (30 Days)
- PALI 10.3M
- MDXH 275.7K
- Earning Date
- PALI 11-11-2025
- MDXH 11-12-2025
- Dividend Yield
- PALI N/A
- MDXH N/A
- EPS Growth
- PALI N/A
- MDXH N/A
- EPS
- PALI N/A
- MDXH N/A
- Revenue
- PALI N/A
- MDXH $98,953,000.00
- Revenue This Year
- PALI N/A
- MDXH $24.43
- Revenue Next Year
- PALI N/A
- MDXH $21.00
- P/E Ratio
- PALI N/A
- MDXH N/A
- Revenue Growth
- PALI N/A
- MDXH 22.56
- 52 Week Low
- PALI $0.53
- MDXH $1.35
- 52 Week High
- PALI $3.44
- MDXH $5.33
- Technical
- Relative Strength Index (RSI)
- PALI 61.09
- MDXH 63.24
- Support Level
- PALI $1.61
- MDXH $4.71
- Resistance Level
- PALI $2.14
- MDXH $5.33
- Average True Range (ATR)
- PALI 0.17
- MDXH 0.28
- MACD
- PALI -0.01
- MDXH 0.05
- Stochastic Oscillator
- PALI 70.09
- MDXH 68.03
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.